Glaukos Corporation was incorporated in Delaware on July 14, 1998. The company is an ophthalmic pharmaceutical and medical technology company focused on developing new drop-free therapies and commercializing related products for the treatment of glaucoma, corneal diseases and retinal diseases. They first developed minimally invasive glaucoma surgery (MIGS) as an alternative to the traditional glaucoma treatment model and launched their first MIGS device in 2012. They also offer a commercialized proprietary bioactivating drug therapy for the treatment of the rare corneal disease keratoconus, which was approved by the U.S. Food and Drug Administration (FDA) in 2016. They are developing a range of platforms to support ongoing pharmaceutical and medical device innovations.